Suspected iron dextran-related adverse drug events in hemodialysis patients.
about
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agentsRole of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patientsSafety concerns about intravenous iron therapy in patients with chronic kidney diseaseIron deficiency in gastrointestinal oncologyOn the relative safety of parenteral iron formulationsFerumoxytol for the treatment of iron deficiency.Is low-molecular weight iron dextran really the most risky iron?--Unconvincing data from an unconvincing study.Anaphylactic Shock Secondary to Intravenous Iron Sucrose in Chronic Kidney DiseaseDiagnosis and management of iron deficiency anemia in patients with IBD.Postoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement.Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study.Intravenous iron dextran as a component of anemia management in chronic kidney disease: a report of safety and efficacy.Ferumoxytol for treating iron deficiency anemia in CKDSafety issues with intravenous iron products in the management of anemia in chronic kidney diseaseDirect Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia.Exploiting endocytosis for nanomedicines.Safety of intravenous iron use in chronic kidney disease.Treatment of Iron Deficiency with or without Anaemia with Intravenous Ferric Carboxymaltose in Gynaecological Practices - A Non-Interventional Study.State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease.Hypersensitivity to intravenous iron: classification, terminology, mechanisms and managementIron Deficiency in Long-Term Parenteral Nutrition Therapy.Intravenous iron sucrose for children with iron deficiency anemia: a single institution study.Acute, severe and anaphylactoid reactions are very rare with low-molecular-weight iron dextran, CosmoFer.Update on adverse drug events associated with parenteral iron.The comparative safety of various intravenous iron preparations in chronic kidney disease patients.Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.Correction of iron deficiency anaemia using IV CosmoFer in CKD patients with asthma: a prospective study.Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis
P2860
Q24186166-A55E49B4-1DB9-40A1-87AD-36AF317E5ED9Q24203798-335A994B-E137-4A3A-81AD-C315922C3743Q26764881-553B7251-8915-4782-9622-7B18E2DA3D32Q27023196-5445C1E9-89D4-4C6C-9F9F-BF3ED79500D3Q28262418-94A37219-8E30-44BF-9F9F-F73AC2539B43Q30454001-CAE04959-7157-4984-B4BD-A1B0FB01CD36Q31045009-87E7A1FA-3CFE-4345-B191-E21CCADEA63CQ33165868-7297EC13-CCD0-4D79-B271-3D37C1CC2991Q34141999-033BBC74-0322-482B-A1B0-FDCB5153D8EBQ34385089-98DE1D04-2A5D-49EA-9AC6-E9FEA355361EQ36263980-5BE876D6-80C5-4B02-951D-458F989841F2Q36734021-6A2C8321-5AEE-4BC7-A775-C777322C3DEBQ36796801-607D6109-5AF6-49B2-AE52-51D42BBC7B7DQ37161960-93FF4AB3-1ABB-47ED-A886-5F5D53A763EFQ37171855-5F9DEBDC-FC8D-4A4C-8BD2-C9164BBA3BCBQ37258701-C050B1DD-2AED-4D09-92B1-9F7377078959Q37320585-307D21AE-78D7-43F9-8CAB-604B9FC91D87Q37660608-3C08575C-95E9-4B63-B30E-71A9A823BB40Q38037260-962E749E-677D-493D-8C72-5A7F7A9EE929Q38564991-EE9124E4-E565-4C15-8690-FF48EEF4AB0CQ40941731-F55313CA-9895-4A76-B66C-7B6861884A76Q41260278-696F59B2-04AD-441B-AE1A-EB1CAF907FF4Q42682575-7CBED1CB-7DE2-44D7-A495-DB4FF0B37E46Q46212164-F97AA225-B173-45EB-B074-4411479295D9Q46459696-F30D9522-DDED-44C9-8904-02BABDED3295Q47103693-061C4257-ADC1-4544-A0F7-D63668192DE2Q48787043-926D40BE-D82C-4525-BFCE-C1197D8AB644Q58908160-5C112CE9-C637-4D76-9BD2-AF8A47CE3D73
P2860
Suspected iron dextran-related adverse drug events in hemodialysis patients.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Suspected iron dextran-related adverse drug events in hemodialysis patients.
@en
Suspected iron dextran-related adverse drug events in hemodialysis patients.
@nl
type
label
Suspected iron dextran-related adverse drug events in hemodialysis patients.
@en
Suspected iron dextran-related adverse drug events in hemodialysis patients.
@nl
prefLabel
Suspected iron dextran-related adverse drug events in hemodialysis patients.
@en
Suspected iron dextran-related adverse drug events in hemodialysis patients.
@nl
P2093
P1476
Suspected iron dextran-related adverse drug events in hemodialysis patients.
@en
P2093
P304
P356
10.1016/S0272-6386(01)80123-2
P577
2001-04-01T00:00:00Z